Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly
evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to …

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve
around the world, generating new variants that are of concern on the basis of their potential …

The sensitivity of SARS-CoV-2 variants of concern (VOCs) to neutralizing antibodies has
largely been studied in the context of key receptor binding domain (RBD) mutations …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Mutations in the spike glycoproteins of SARS-CoV-2 variants of concern have independently
been shown to enhance aspects of spike protein fitness. Here, we describe an antibody …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …

The initial severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
subvariants, BA. 1 and BA. 2, are being progressively displaced by BA. 5 in many countries …